Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication

Virology

Volumn 430, Issue 1, 2012, Pages 53-62

  Xiang, Jinhua ^a   McLinden, James H ^a   Kaufman, Thomas M ^a   Mohr, Emma L ^a,b   Bhattarai, Nirjal ^a,b   Chang, Qing ^a   Stapleton, Jack T ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Envelope glycoprotein; GBV C; HIV

Indexed keywords

GLYCOPROTEIN E2;

ARTICLE; CONTROLLED STUDY; HEPATITIS G VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; LEUKEMIA CELL LINE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; GB VIRUS C; HIV; HUMANS; JURKAT CELLS; MICROBIAL INTERACTIONS; PROTEIN STRUCTURE, TERTIARY; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

GB VIRUS C; YELLOW FEVER VIRUS;

EID: 84861818951     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.04.019     Document Type: Article

References (55)

1. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells. J. Virol. 1986, 59:284-291.
2. Alter H.J. G-pers creepers, where'd you get those papers? A reassessment of the literature on the hepatitis G virus. Transfusion 1997, 37:569-572.
3. Alter H.J., Nakatsuji Y., Melpolder J., Wages J., Wesley R., Shih J.W.-K., Kim J.P. The Incidence of Transfusion-Associated Hepatitis G Virus Infection and its relation to liver disease. N. Engl. J. Med. 1997, 336:747-754.
4. Alter M.J., Gallagher M., Morris T.T., Moyer L.A., Meeks E.L., Krawczynski K., Kim J.P., Margolis H.S. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. N. Engl. J. Med. 1997, 336:741-746.
5. Belyaev A.S., Chong S., Novikov A., Kongpachith A., Masiarz F.R., Lim M., Kim J.P. Hepatitis G virus encodes protease activities which can effect processing of the virus putative nonstructural proteins. J. Virol. 1998, 72:868-872.
6. Bjorkman P., Flamholc L., Naucler A., Molnegren V., Wallmark E., Widell A. GB Virus C during the natural course of HIV-1 infection: viremia at diagnosis does not predict mortality. AIDS 2004, 18:877-886.
7. Bjorkman P., Flamholc L., Molnegren V., Marshall A., Guner N., Widell A. Enhanced and resumed GB virus C replication in HIV-1-infected individuals receiving HAART. AIDS 2007, 21:1641-1643.
8. Dawson G.J., Schlauder G.G., Pilot-Matias T.J., Thiele D., Leary T.P., Murphy P., Rosenblatt J.E., Simons N., Martinson E.A., Gutierrez R.A., Lentino J.R., Pachucki C., Muerhoff A.S., Widell A., Tegtmeier G., Desai S., Mushahwar I.K. Prevalence studies of GB virus-C using reverse-transcriptase-polymerase chain reaction. J. Med. Virol. 1996, 50:97-103.
9. Fogeda M., Navas S., Martin J., Casqueiro M., Rodriguez E., Arocena C., Carreno V. In vitro infection of human peripheral blood mononuclear cells by GB virus C/Hepatitis G virus. J. Virol. 1999, 73:4052-4061.
10. George S.L., Xiang J., Stapleton J.T. Clinical isolates of GB virus type C vary in their ability to persist and replicate in peripheral blood mononuclear cell cultures. Virology 2003, 316:191-201.
11. George S.L., Varmaz D., Stapleton J.T. GB virus C replicates in primary T and B lymphocytes. J. Infect. Dis. 2006, 193:451-454.
12. Hassoba H.M., Pessoa M.G., Terrault N.A., Lewis N.J., Hayden M., Hunt J.C., Qiu X., Lou S.C., Wright T.L. Antienvelope antibodies are protective against GBV-C reinfection: evidence from the liver transplant model. J. Med. Virol. 1998, 56:253-258.
13. Herrera E., Tenckhoff S., Gomara M.J., Galatola R., Bleda M.J., Gil C., Ercilla G., Gatell J.M., Tillmann H.L., Haro I. Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. J. Med. Chem. 2010, 53:6054-6063.
14. Heuft H.G., Berg T., Schreier E., Kunkel U., Tacke M., Schwella N., Hopf U., Salama A., Huhn D. Epidemiological and clinical aspects of hepatitis G virus infection in blood donors and immunocompromised recipients of HGV-contaminated blood. Vox Sanguinis 1998, 74:161-167.
15. Hitzler W.E., Runkel S. Prevalence, persistence and liver enzyme levels of HGV RNA-positive blood donors determined by large-scale screening and transmission by blood components. Clin. Lab. 2004, 50:25-31.
16. Jung S., Knauer O., Donhauser N., Eichenmuller M., Helm M., Fleckenstein B., Reil H. Inhibition of HIV strains by GB virus C in cell culture can be mediated by CD4 and CD8 T-lymphocyte derived soluble factors. AIDS 2005, 19:12567-12572.
17. Jung S., Eichenmueller M., Donhauser N., Neipel F., Engel A.M., Hess G., Fleckenstein B., Reil H. HIV entry inhibition by the envelope 2 glycoprotein of GB virus C. AIDS 2007, 21:645-647.
18. Kim J.P., Fry K.E. Molecular characterization of the hepatitis G virus. J. Viral Hepat. 1997, 4:77-79.
19. Koedel Y., Eissmann K., Wend H., Fleckenstein B., Reil H. Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. J. Virol. 2011, 85:7037-7047.
20. Krey T., d'Alayer J., Kikuti C.M., Saulnier A., Damier-Piolle L., Petitpas I., Johansson D.X., Tawar R.G., Baron B., Robert B., England P., Persson M.A.A., Martin A., Rey F.A. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog. 2010, 6. e1000762-1-11.
21. Larios C., Casas J., Alsina M.A., Mestres C., Gomara M.J., Haro I. Characterization of a putatitve fusogenic sequence in the E2 hepatitis G protein. Arch. Biochem. Biophys. 2005, 442:149-159.
22. Laskus T., Radkowski M., Wang L.-F., Vargas H., Rakela J. Lack of evidence for hepatitis G virus replication in the livers of patients coinfected with hepatitis C virus and G virus. J. Virol. 1997, 71:7804-7806.
23. Leary T.P., Muerhoff A.S., Simons J.N., Pilot-Matias T.J., Erker J.C., Chalmers M.L., Schlauder G.G., Dawson G.J., Desai S.M., Mushahwar I.K. Sequence and genomic organization of GBV-C: A novel member of the Flaviviridae associated with human non-A-E hepatitis. J. Med. Virol. 1996, 48:60-67.
24. Lefrère J.J., Roudot-Thoraval F., Morand-Joubert L., Petit J.-C., Lerable J., Thauvin M., Mariotti M. Carriage of GB Virus C/Hepatitis G Virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons. J. Infect. Dis. 1999, 179:783-789.
25. Lindenbach B.D., Rice C.M. Molecular biology of Flaviviruses. Adv. Virus Res. 2003, 59:23-61.
26. Linnen J., Wages J., Zhang-Keck Z.-Y., Fry K.E., Krawczynski K.Z., Alter H., Koonin E., Gallagher M., Alter M., Hadziyannis S., Karayiannis P., Fung K., Nakatsuji Y., Shih J.W.K., Piatak M., Hoover C., Fernandez J., Chen S., Zou J.-C., Morris T., Hyams K.C., Ismay S., Lifson J.D., Hess G., Foung S.K.H., Thomas H., Bradley D., Margolis H., Kim J.P. Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent. Science 1996, 271:505-508.
27. Maidana Giret M.T., Silva T.M., Sauer M.M., Tomiyama H., Levi J.E., Bassichetto K.C., Nishiya A., Diaz R.S., Sabino E.C., Palacios R., Kallas E.G. GBV-C infection modulates T cell activation in recently HIV-infected subjects and is independent of HIV-1 viral load. AIDS 2009, 23:2277-2287.
28. McLinden J.H., Kaufman T.M., Xiang J., Chang Q., Klinzman D., Engel A.M., Hess G., Schmidt U., Houghton M., Stapleton J.T. Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding. J. Virol. 2006, 80:12131-12140.
29. Mohr E.L., Stapleton J.T. GB virus type C interactions with HIV: The role of envelope glycoproteins. J. Viral Hepat. 2009, 16:757-758.
30. Mohr E.L., Xiang J., McLinden J.H., Kaufman T.M., Montefiori D.C., Klinzman D., Stapleton J.T. GB Virus C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates. J. Immunol. 2010, 185:4496-4505.
31. Nattermann J., Nischalke H.D., Kupfer B., Rockstroh J., Hess L., Sauerbruch T., Spengler U. Regulation of CC chemokine receptor 5 in Hepatitis G virus infection. AIDS 2003, 17:1457-1462.
32. Pessoa M.G., Terrault N.A., Detmer J., Kolberg J., Colllins M., Hassoba H.M., Wright T.L. Quantitation of hepatitis G and C viruses in the liver: evidence that hepatitis G virus is not hepatotropic. Hepatology 1998, 27:877-880.
33. Pilot-Matias T.J., Carrick R.J., Coleman P.F., Leary T.P., Surowy T.K., Simons J.N., Muerhoff A.S., Buijk S.L., Chalmers M.L., Dawson G.J., Desai S.M., Mushahwar I.K. Expression of the GB virus C E2 glycoprotein using the Semliki Forest virus vector system and its utility as a serologic marker. Virology 1996, 225:282-292.
34. Rey D., Vidinic-Moularde J., Meyer P., Schmitt C., Fritsch S., Lang J.M., Stoll-Keller F. High prevalence of GB virus C/hepatitis G virus RNA and antibodies in patients infected with human immunodeficiency virus type 1. Eur. J. Clin. Microbiol. Infect. Dis. 2000, 19:721-724.
35. Rydze, R.T., Bhattarai, N., Stapleton, J.T. GB virus C infection is associated with a reduced rate of reactivation of latent HIV and protection against activation-induced T cell death. Antivir Ther, In Press.
36. Schwarze-Zander C., Neibecker M., Othman S., Tural C., Clotet B., Blackard J.T., Kupfer B., Luechters G., Chung R.T., Rockstroh J.K., Spengler U. GB virus C coinfection in advanced HIV type-1 disease is associated with low CCR5 and CXCR4 surface expression on CD4(+) T-cells. Antivir. Ther. 2010, 15:745-752.
37. Simons J.N., Leary T.P., Dawson G.J., Pilot-Matias T.J., Muerhoff A.S., Schlauder G.G., Desai S.M., Mushahwar I.K. Isolation of novel virus-like sequences associated with human hepatitis. Nature Med. 1995, 1:564-569.
38. Stapleton J.T. GB virus type C/hepatitis G virus. Semin. Liver Dis. 2003, 23:137-148.
39. Stapleton J.T., Foung S., Muerhoff A.S., Bukh J., Simmonds P. The GB viruses: A Review and proposed classification of GBV-A, GBV-C(HGV), and GBV-D in genus Pegivirus within the family Flaviviridae. J. Gen. Virol. 2011, 92:233-246.
40. Tacke M., Schmolke S., Schlueter V., Sauleda S., Esteban J.I., Tanaka E., Kiyosawa K., Alter H.J., Schmitt U., Hess G., Ofenloch-Haehnle B., Engel A.M. Humoral immune response to the E2 protein of hepatitis G virus is associated with long-term recovery from infection and reveals a high frequency of hepatitis G virus exposure among healthy blood donors. Hepatology 1997, 26:1626-1633.
41. Tanaka E., Alter H.J., Nakatsuji Y., Shih J.W., Kim J.P., Matsumoto A., Kobayashi M., Kiyosawa K. Effect of hepatitis G virus infection on chronic hepatitis C. Ann. Intern. Med. 1996, 125:740-743.
42. Tanaka E., Kiyosawa K., Shimoda K., Hino K., Tacke M., Schmolke S., Engel A.M., Hess G. Evolution of hepatitis G virus infection and antibody response to envelope protein in patients with transfusion-associated non-A, non-B hepatitis. J. Viral Hepat. 1998, 5:153-159.
43. Thomas D.L., Vlahov D., Alter H.J., Marshall R., Astemborski J., Nelson K.E. Association of antibody to GB virus C (hepatitis G virus) with viral clearance and protection from reinfection. J. Infect. Dis. 1998, 177:539-542.
44. Tillmann H.L., Heringlake S., Trauwein C., Meissner D., Nashan B., Schlitt H.J., Kratochvil J., Hunt J., Qiu X., Lou C., Pichlmayr R., Manns M.P. Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus C de novo infection. Hepatology 1998, 28:379-384.
45. Tillmann H.L., Heiken H., Knapik-Botor A., Heringlake S., Ockenga J., Wilber J.C., Goergen B., Detmer J., Manns M.P., Stoll M., Schmidt R.E., Manns M.P. Infection with GB virus C and reduced mortality among HIV-infected patients. N. Engl. J. Med. 2001, 345:715-724.
46. Van der Bij A.K., Kloosterboer N., Prins M., Boeser-Nunnink B., Geskus R.B., Lange J.M.A., Coutinho R.A., Schuitemaker H. GB Virus C coinfection and HIV-1 disease progression: The Amsterdam cohort study. J. Infect. Dis. 2005, 191:678-685.
47. Williams C.F., Klinzman D., Yamashita T.E., Xiang J., Polgreen P.M., Rinaldo C., Liu C., Phair J., Margolick J.B., Zdunek D., Hess G., Stapleton J.T. Persistent GB virus C infection and survival in HIV-infected men. N. Engl. J. Med. 2004, 350:981-990.
48. Wunschmann S., Klinzman D., Medh J., Klinzman D., Schmidt W.N., Stapleton J.T. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low density lipoprotein receptor. J. Virol. 2000, 74:10055-10062.
49. Xiang J., Wunschmann S., Schmidt W.N., Shao J., Stapleton J.T. Full-length GB Virus C (Hepatitis G Virus) RNA transcripts are infectious in primary CD4-Positive T cells. J. Virol. 2000, 74:9125-9133.
50. Xiang J., Wunschmann S., Diekema D.J., Klinzman D., Patrick K.D., George S.L., Stapleton J.T. Effect of coinfection with GB Virus C (Hepatitis G virus) on survival among patients with HIV infection. N. Engl. J. Med. 2001, 345:707-714.
51. Xiang J., George S.L., Wunschmann S., Chang Q., Klinzman D., Stapleton J.T. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1a, MIP-1b, and SDF-1. Lancet 2004, 363:2040-2046.
52. Xiang J., McLinden J.H., Chang Q., Kaufman T.M., Stapleton J.T. An 85 amino acid segment of the GB Virus type C NS5A phosphoprotein inhibits HIV-1 replication in CD4+ Jurkat T-cells. Proc. Natl. Acad. Sci. USA 2006, 103:15570-15575.
53. Xiang J., McLinden J.H., Chang Q., Jordan E.L., Stapleton J.T. Characterization of a peptide domain within the GB virus C NS5A phosphoprotein that inhibits HIV replication. PLoS One 2008, 3(e2580):1-10.
54. Xiang J., McLinden J.H., Rydze R.A., Chang Q., Kaufman T.M., Klinzman D., Stapleton J.T. Viruses within the Flaviviridae decrease CD4 expression and inhibit HIV replication in human CD4+ cells. J. Immunol. 2009, 183:7860-7869.
55. Zhang W., Chaloner K., Tillmann H.L., Williams C.F., Stapleton J.T. Effect of early and late GBV-C viremia on survival of HIV infected individuals: A meta-analysis. HIV Med. 2006, 7:173-180.